Baidu
map

行业标准制定小组Align Biopharma成员增加至23名

2017-07-25 佚名 MedSci原创

-行业领先企业携手制定并执行新的技术标准

上海2017年7月24日电 /美通社/ -- 14家业内领先的生物制药公司以及技术和服务供应商于今日加入了生命科学行业技术标准制定小组Align BiopharmaTM。自成立半年以来,Align Biopharma作为开放式技术标准的制定者和执行者,其影响力在业内迅速提升。Align Biopharma目前共有23名成员,致力于让医学专业人士与生命科学企业之间的数字化沟通更加方便快捷。

Shire公司是Align Biopharma的新成员之一,公司副总裁及商业IT部门主管Ed Kloskowsk表示:“统一的技术标准能让利益相关者随时随地获取所需信息,因而有助于解决全行业面临的重大商业问题。Shire致力于解决医疗服务匮乏的患者群体的需求。我们与Align Biopharma携手合作,实现协调一致的数字化沟通,最终让患者受益,这为我们服务患者开辟了另一条路径。”

Exostar、Gigya、Janrain、Okta等技术供应商,以及埃森哲、高知特、德勤、Mavens等服务供应商,这些业内领先企业正在协助定义及审核Align Biopharma的开放式技术标准,以保证其在业内得到广泛的认可。

“整个生命科学行业对Align Biopharma开展的工作反响热烈。”Align Biopharma主席Henry Levy表示,“显然,这是一个绝佳的机会去改善医学专业人士对数字化工作的体验。为此我们正在招贤纳士,吸引最优秀的专家,协力制定标准,从而帮助医学专业人士更加方便地获取所需的重要诊疗信息。”

Align Biopharma的首个标准涉及身份认证管理,预计将于2017年夏实行。这项标准定义了医学专业人士单点登录服务解决方案的技术要求。Align Biopharma已着手开发第二项标准,该标准涉“同意与偏好管理”,能让医学专业人士向各个生命科学企业明确其沟通偏好的方式并保持一致。Align Biopharma预计将于今年下半年发布其同意及沟通偏好管理标准,并接受公开评审和反馈。

Align Biopharma新成员如是说:

埃森哲生命医学北美区高级董事总经理Kevin Julian表示:“埃森哲很高兴能成为Align Biopharma的一员,携手制定技术标准,造福医疗界,让患者更快得到治疗。”

“Adobe很高兴能加入Align Biopharma。”Adobe医疗行业战略与市场营销负责人Thomas Swanson表示,“开放式技术标准提供了可靠的行业标准,能让数字技术在医疗体验转型的过程中发挥助力作用。”

“随着生命科学企业日益关注数字化转型,技术标准对于在不同系统和平台之间实现有效的信息共享至关重要。”高知特高级副总裁及全球生命科学市场负责人Bhaskar Sambasivan表示,“我们期待继续推进这项重大的行业举措,促成生命科学企业与医学专业人士的合作,提升对患者的关护。”

“美国的医疗系统非常复杂,但通过制定和执行新标准,Align Biopharma能够为医学专业人士提高数字化能力。”德勤咨询公司首席顾问及数字化生命科学主管表示,“这些新技术不仅能让供应商受益,也能实现病历的快速读取,从而造福患者,为医生节省更多时间用于患者的治疗。”

“Align Biopharma制定的标准不仅将惠及医疗服务供应商和制药公司,还将造福患者,为他们提供明确而统一的流程来批准使用其医疗数据,同时保障其隐私和个人信息安全。”Gigya首席策略官Eyal Magen表示,“Gigya已准备好全力投身于这项重大事业。”

“能加入Align Biopharma让我们兴奋不已,因为我们致力于开拓创新,与业界携手合作,共享创新成果。”Janrain公司首席执行官Jim Kaskade表示,“作为Align Biopharma的一员,我们热切地期望能与其他领先企业开展合作,贡献我们的知识和经验。我们不仅致力于提升医学专业人士的体验,而且力图改善患者和客户组织的体验。”

“Align Biopharma制定技术标准的目的与Mavens的使命不谋而合,那便是整合业内顶尖的云技术,打造连接患者与医疗的软件解决方案,并促进全球医疗行业发展。”Mavens公司首席执行官Prasad Kanumury表示,“我们很高兴能投身这项重大事业,为医学专业人士带来更多便利,让他们有更多时间专注于患者。”

“Align Biopharma的身份标准能减少医学专业人士需要记忆的账户和密码,让他们能将宝贵的时间用到更有价值的地方 -- 患者关怀,而不是重置密码。”Okta公司业务开发副总裁Chuck Fontana表示,“作为Align Biopharma成员,我们期待继续协助医疗服务供应商在不牺牲安全性以及用户体验的前提下采用新技术。”

欲了解更多信息

Connect with Align Biopharma on LinkedIn: linkedin.com/company/align-biopharma Follow @alignbiopharma on Twitter: twitter.com/alignbiopharma

请关注Align Biopharma的领英账号:linkedin.com/company/align-biopharma

请关注Align Biopharma的Twitter账号@alignbiopharma:twitter.com/alignbiopharma

关于Align Biopharma

Align Biopharma是由全球顶尖制药公司和Veeva Systems共同成立的行业标准组织,成员包括20多家业内领先的制药公司、技术公司和服务供应商,致力于让医学专业人士与生命科学行业之间的沟通更加方便快捷。欲了解更多信息,请访问AlignBiopharma.org。

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917581, encodeId=892b191e58147, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu May 24 17:41:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707528, encodeId=87481e075286f, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Wed May 16 23:41:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787289, encodeId=08d51e87289fb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 12 13:41:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908286, encodeId=1f72190828644, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Oct 10 04:41:00 CST 2017, time=2017-10-10, status=1, ipAttribution=)]
    2018-05-24 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1917581, encodeId=892b191e58147, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu May 24 17:41:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707528, encodeId=87481e075286f, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Wed May 16 23:41:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787289, encodeId=08d51e87289fb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 12 13:41:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908286, encodeId=1f72190828644, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Oct 10 04:41:00 CST 2017, time=2017-10-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1917581, encodeId=892b191e58147, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu May 24 17:41:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707528, encodeId=87481e075286f, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Wed May 16 23:41:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787289, encodeId=08d51e87289fb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 12 13:41:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908286, encodeId=1f72190828644, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Oct 10 04:41:00 CST 2017, time=2017-10-10, status=1, ipAttribution=)]
    2018-02-12 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=1917581, encodeId=892b191e58147, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu May 24 17:41:00 CST 2018, time=2018-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707528, encodeId=87481e075286f, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Wed May 16 23:41:00 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787289, encodeId=08d51e87289fb, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 12 13:41:00 CST 2018, time=2018-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908286, encodeId=1f72190828644, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Oct 10 04:41:00 CST 2017, time=2017-10-10, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map